News | April 05, 2021
GlaxoSmithKline approves sale of Vemgal plant
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
DHL and other logistics companies were already transporting pharmaceutical products at minus 70°C in Schaumaplast boxes packed with dry ice before the coronavirus pandemic
The company is expecting tremendous growth and a better quarterly performance
Subscribe To Our Newsletter & Stay Updated
